ProSurg Could Capitalize on WLF Decision To Market InjecTx For BPH
This article was originally published in The Gray Sheet
Executive Summary
Prosurg's future marketing strategy for the InjecTx transurethral injection system depends heavily on FDA's interpretation of the recent federal court decision in Washington Legal Foundation v. Henney.
You may also be interested in...
Buckman Case Testimony At Odds With FDA Pedicle Screw Enforcement
A ruling by the U.S. Supreme Court in the pedicle screw case, Buckman Co. v. Plaintiffs' Legal Committee, could influence FDA's enforcement of 21 CFR 801.4 for manufacturers that are aware of off-label use with their products.
Buckman Case Testimony At Odds With FDA Pedicle Screw Enforcement
A ruling by the U.S. Supreme Court in the pedicle screw case, Buckman Co. v. Plaintiffs' Legal Committee, could influence FDA's enforcement of 21 CFR 801.4 for manufacturers that are aware of off-label use with their products.
WLF Decision Opens Door To Off-Label Promotion With Journal Reprints
Manufacturers can promote products for off-label uses with studies sponsored by competitors, according to the July 28 federal court decision against the FDA Modernization Act in Washington Legal Foundation v. Henney.